I'll start by reading the resume file in full.

I've read the resume file. Key point: it says all analysis (including Wave 2 LIANA/cell2location, spatial neighbourhood, and the scientific-reviewer pass) is **already complete and verified** in the LIVE run directory — so the instruction "finish Wave 2 / spatial / review" is stale; my job is synthesis only, with no re-running of analyses. Let me verify what is on disk before writing anything.

LIVE run directory confirmed. Now let me inventory the actual deliverables and check the two acceptance conditions from the re-review.

The `report/FINAL_REPORT.md` is not a synthesis — it's a pasted transcript of the prior turn's narration. There are 0 claims and no synthesis. Acceptance conditions checked so far: both training-history stubs are gone (N1 resolved). Let me confirm N2 and load the required contracts.

Both acceptance conditions are resolved: N1 stubs deleted, N2 values recomputed and matching (tumour 7,545.0/3,708.5 = 2.03×; adjacent-normal 2,388.0/2,083.75 = 1.15×). Now reading the verified panel reports for synthesis.

State confirmed. Let me now pin down the paper's own per-panel claims (for the panel-by-paper comparison) and locate the repo README I must update.

Both acceptance conditions confirmed resolved (history CSVs absent; medians now 7,545.0/3,708.5 and 2,388.0/2,083.75). Writing the synthesis deliverables now.

File writes are restricted to my session run directory (`76d40ca3`), not LIVE. I'll deliver the synthesis into my own run and check how provenance scoping behaves.

Provenance is hard-scoped to my session run, so I'll stage the small evidence tables and reports there (not the large data). First, locating the exact evidence filenames.

Table contents confirm every number. One refinement: the 4F contrast n is 251 unadjusted / 246 adjusted. Writing the report into my delivery run.

All 24 staged artifacts are registered in the delivery run. Now adding the text workflow to the report and recording claims.

Claims recorded successfully — 15 claims, every evidence pointer verified. Updating the provenance section to reflect that.

The write hook blocks edits outside the session workspace, so the top-level README cannot be modified from this run. I'll stage the exact patch for it inside the delivery run and report that clearly.

Round 2 is delivered. The full report is at `report/FINAL_REPORT.md`, with `report/panel_by_paper_comparison.md`, `report/workflow_diagram.svg` (plus a mermaid version in §7), and 15 verified claim–evidence objects in `evidence/claims.json`.

## Executive summary

The six paper panels were rebuilt end-to-end and independently reviewed. Direction and shape mostly agree with the paper, but strength is materially weaker, and several claims are not supported at the standard the paper implies.

**What is solid:**
- **No germline genetic support.** 0/8 LUAD+SCLC GWAS studies carry a CD276 credible set within ±500 kb; 0/67 L2G loci are from LUAD/SCLC[[cl:C101]]. The regulatory signal is real but annotation-only — 839 CD276-linked lung elements, 77 within ±500 kb, 29 at the pre-declared threshold, promoter score 0.973[[cl:C103]].
- **Not tumour-restricted.** 36.53% detection in normal lung macrophages and 30.84% in LUAD fibroblasts[[cl:C111]] — the most decision-relevant negative.
- **Not differentially expressed** in any of 15 disease-vs-normal contrasts (min padj 0.291)[[cl:C105]].
- **Survival is stage-dependent.** Unadjusted Q4-vs-Q1 OS 1.80 (p = 0.0051) and DSS 1.86 (p = 0.0206) reproduce the paper's direction[[cl:C113]]; adjusted OS p = 0.106 and DSS p = 0.249 do not[[cl:C114]].
- **No unique CAF signalling.** An ECM/proteolysis programme (THBS2–CD47, PLAU, SERPINE1) is enriched, but it is a rank-based, depth-confounded candidate set with no formal test[[cl:C107]].
- **The immune-hot niche is an artifact.** Absolute abundance tracks a 2.03× capture-depth difference and fails an interior-spot sensitivity check[[cl:C110]]; the depth-robust composition signal is malignant +3.79 pp with endothelial (−2.03), NK (−0.49) and macrophage (−0.40) depletion[[cl:C109]].
- **Not essential** (mean CERES −0.230 LUAD; 1/46 below −0.5)[[cl:C117]].

## Panel-by-panel vs the paper

| Panel | Status |
|---|---|
| 4A genetics | **Disagree** on genetics; **agree** on regulatory annotation only |
| 4B/4C scRNA | Atlas reproduced (413,996 cells / 80 donors / 15 types)[[cl:C104]]; **disagree** on "CD276-associated" |
| 4D/S5A LIANA | **Weaker / disagree** on "unique" |
| 4E/S5B Visium | **Weaker / disagree** on "immune-hot" |
| 4F survival | **Agree unadjusted, weaker adjusted** |
| Tahoe/DepMap | Tahoe **inconclusive** (blocked)[[cl:C116]]; DepMap **agree** (not essential) |

## Mandatory caveats (unsoftened)

- Visium stratification is detection-based; adjacent-normal "high" groups are degenerate (median CD276 = 0.0 in 8/10 sections)[[cl:C112]].
- Permutation p-values are anticonservative (floor 1/1001); the section bootstrap overstates precision (5 donors per histology).
- LIANA has no formal test, no FDR, no depth matching; SCLC has 2 donors with ≥10 high cells.
- Spatial mapping ran 3,000 CPU epochs vs the paper's 10,000 on H100; absolute abundances are not directly comparable.
- Tahoe-100M is **not assessable / no evidence either way** — it is not "non-material."

## Overall assessment

**CD276 is a low-confidence, expression-defined target.** Its therapeutic interest rests on expression prevalence in some tumour compartments and on existing clinical-stage agents, not on target-validation biology. The strongest reproducible statements are negative: not tumour-restricted, not differentially expressed, not essential, not independently prognostic. This **supports** round 1's low-confidence stance but **revises** its SCLC-over-LUAD staging — the only quantitative positives here are in LUAD.

## Deliverable status

- Claims: **filed successfully** — 15 claims, 30 evidence pointers verified (the previous session's failure is resolved).
- README: **blocked** — the run's write policy forbids edits outside the session workspace. The exact ready-to-paste section is staged at `report/README_update_proposed.md`.
- Commit/push: **nothing to commit** — the working tree is clean and `runs/` is gitignored. The README cannot be updated until the patch is applied outside this run.

**Suggested next steps:**
1. **Apply the staged README patch** from `report/README_update_proposed.md`, then commit and push — this is the only remaining item from the delivery checklist.
2. **Run a depth-matched CAF contrast** to test whether the ECM programme survives proper depth and subtype matching — the strongest remaining positive in the package.
3. **Enable the Tahoe-100M track** by preparing the dataset and setting `TAHOE_DATA_PATH`, to close the only unassessable panel.
4. **Test fibroblast disease-vs-normal DE** with additional normal-lung donors — the compartment most relevant to the B7-H3 CAF hypothesis is currently untestable.

Would you like me to pursue any of these?